New York, March 15, 2023 - PRISM MarketView - Tilray Brands, Inc. (Nasdaq: TLRY) has received approval from Portuguese regulators for its first medical cannabis extract, Tilray Oral Solution THC 5 CBD 20, marking a significant advancement in the medical cannabis sector within the country.
- Regulatory Approval for Cannabis Extract: Following its previously approved whole flower THC 18, Tilray has now gained regulatory approval for its cannabis extract in Portugal.
- Enhancing Patient Care: This approval aims to improve the accessibility and quality of medical cannabis for patients in Portugal.
- Anticipated Product Launch: The approved cannabis extract is expected to be available in late spring, providing new therapeutic options for patients with specific conditions.
“This is a monumental step forward for patient care in Portugal. With the approval of our first medical cannabis extract, we are proud to be at the forefront of medical cannabis research and accessibility and continue to demonstrate our commitment to providing innovative, safe, and effective therapeutic options to patients. We continue to pioneer the future of medical cannabis, furthering our mission to empower and inspire individuals to live their best lives.”
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, Inc.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios, and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in over 20 countries and across five continents.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)